Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease in the world. New non-invasive diagnostic tools are needed to promptly treat this disease and avoid its complications. This study aimed to find key metabolites and related variables that could be used to pre...

ver descrição completa

Detalhes bibliográficos
Autores: Mogna-Peláez, P. (Paola)|||/items/5be56ba2-bd55-4ea5-af40-e26118b537d8, Romo‐Hualde, A. (Ana)|||/items/5c6999e7-dcc3-486f-a0e9-aa5bb6d96f4f, Riezu-Boj, J.I. (José Ignacio)|||/items/87349e89-7360-4cdd-81be-2e8a6174b5f6, Milagro-Yoldi, F.I. (Fermín Ignacio)|||/items/07cf7af6-1f5f-4720-8c14-5197a7a724eb, Muñoz-Prieto, D. (David)|||/items/c0b800f6-8ccc-4508-b8ea-6189cc7d8a99, Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1d, Elorz-Carlón, M. (Mariana)|||/items/2bb34072-5d36-4e93-baa5-317e6f1e8247, Benito-Boíllos, A. (Alberto)|||/items/36f5562b-2392-4f6a-a747-a57b8b201069, Monreal, J.I. (José Ignacio)|||/items/54707c2a-e68a-4e73-9141-0276a5bc7a2b, Tur, J.A. (Josep A.)|||/items/de6900c2-c677-4762-9a97-8e585d1c019e, Martinez, J.A. (José Alfredo)|||/items/6a3581ea-897b-4439-a95c-19301775e131, Abete, I. (Itziar)|||/items/2a1e4080-f97c-44d3-9098-309677a889fb, Zulet, M.A. (María Ángeles)|||/items/0a10c4f7-ed81-4b2e-bffe-fbcb7fccd239
Formato: artículo
Fecha de publicación:2024
País:España
Recursos:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/117295
Acesso em linha:https://hdl.handle.net/10171/117295
Access Level:acceso abierto
Palavra-chave:Insulin resistance
Isoliquiritigenin
Metabolomics
Nonalcoholic fatty liver disease
Visceral adipose tissue
id ES_0ca9016c867a104c5eb7c065b577bb3e
oai_identifier_str oai:dadun.unav.edu:10171/117295
network_acronym_str ES
network_name_str España
repository_id_str
spelling Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver diseaseMogna-Peláez, P. (Paola)|||/items/5be56ba2-bd55-4ea5-af40-e26118b537d8Romo‐Hualde, A. (Ana)|||/items/5c6999e7-dcc3-486f-a0e9-aa5bb6d96f4fRiezu-Boj, J.I. (José Ignacio)|||/items/87349e89-7360-4cdd-81be-2e8a6174b5f6Milagro-Yoldi, F.I. (Fermín Ignacio)|||/items/07cf7af6-1f5f-4720-8c14-5197a7a724ebMuñoz-Prieto, D. (David)|||/items/c0b800f6-8ccc-4508-b8ea-6189cc7d8a99Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1dElorz-Carlón, M. (Mariana)|||/items/2bb34072-5d36-4e93-baa5-317e6f1e8247Benito-Boíllos, A. (Alberto)|||/items/36f5562b-2392-4f6a-a747-a57b8b201069Monreal, J.I. (José Ignacio)|||/items/54707c2a-e68a-4e73-9141-0276a5bc7a2bTur, J.A. (Josep A.)|||/items/de6900c2-c677-4762-9a97-8e585d1c019eMartinez, J.A. (José Alfredo)|||/items/6a3581ea-897b-4439-a95c-19301775e131Abete, I. (Itziar)|||/items/2a1e4080-f97c-44d3-9098-309677a889fbZulet, M.A. (María Ángeles)|||/items/0a10c4f7-ed81-4b2e-bffe-fbcb7fccd239Insulin resistanceIsoliquiritigeninMetabolomicsNonalcoholic fatty liver diseaseVisceral adipose tissueNonalcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease in the world. New non-invasive diagnostic tools are needed to promptly treat this disease and avoid its complications. This study aimed to find key metabolites and related variables that could be used to predict and diagnose NAFLD. Ninety-eight subjects with NAFLD and 45 controls from the Fatty Liver in Obesity (FLiO) Study (NCT03183193) were analyzed. NAFLD was diagnosed and graded by ultrasound and classified into two groups: 0 (controls) and ≥ 1 (NAFLD). Hepatic status was additionally assessed through magnetic resonance imaging (MRI), elastography, and determination of transaminases. Anthropometry, body composition (DXA), biochemical parameters, and lifestyle factors were evaluated as well. Non-targeted metabolomics of serum was performed with high-performance liquid chromatography coupled to time-of-flight mass spectrometry (HPLC-TOF-MS). Isoliquiritigenin (ISO) had the strongest association with NAFLD out of the determinant metabolites. Individuals with higher concentrations of ISO had healthier metabolic and hepatic status and were less likely to have NAFLD (OR 0.13). Receiver operating characteristic (ROC) curves demonstrated the predictive power of ISO in panel combination with other NAFLD and IR-related variables, such as visceral adipose tissue (VAT) (AUROC 0.972), adiponectin (AUROC 0.917), plasmatic glucose (AUROC 0.817), and CK18-M30 (AUROC 0.810). Individuals with lower levels of ISO have from 71 to 82% more risk of presenting NAFLD compared to individuals with higher levels. Metabolites such as ISO, in combination with visceral adipose tissue, IR, and related markers, constitute a potential non-invasive tool to predict and diagnose NAFLD.Springer NatureDadun. Depósito Académico Digital Universidad de Navarra20242024-01-0120242024-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/117295reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1172952026-06-21T12:47:57Z
dc.title.none.fl_str_mv Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease
title Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease
spellingShingle Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease
Mogna-Peláez, P. (Paola)|||/items/5be56ba2-bd55-4ea5-af40-e26118b537d8
Insulin resistance
Isoliquiritigenin
Metabolomics
Nonalcoholic fatty liver disease
Visceral adipose tissue
title_short Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease
title_full Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease
title_fullStr Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease
title_full_unstemmed Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease
title_sort Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease
dc.creator.none.fl_str_mv Mogna-Peláez, P. (Paola)|||/items/5be56ba2-bd55-4ea5-af40-e26118b537d8
Romo‐Hualde, A. (Ana)|||/items/5c6999e7-dcc3-486f-a0e9-aa5bb6d96f4f
Riezu-Boj, J.I. (José Ignacio)|||/items/87349e89-7360-4cdd-81be-2e8a6174b5f6
Milagro-Yoldi, F.I. (Fermín Ignacio)|||/items/07cf7af6-1f5f-4720-8c14-5197a7a724eb
Muñoz-Prieto, D. (David)|||/items/c0b800f6-8ccc-4508-b8ea-6189cc7d8a99
Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1d
Elorz-Carlón, M. (Mariana)|||/items/2bb34072-5d36-4e93-baa5-317e6f1e8247
Benito-Boíllos, A. (Alberto)|||/items/36f5562b-2392-4f6a-a747-a57b8b201069
Monreal, J.I. (José Ignacio)|||/items/54707c2a-e68a-4e73-9141-0276a5bc7a2b
Tur, J.A. (Josep A.)|||/items/de6900c2-c677-4762-9a97-8e585d1c019e
Martinez, J.A. (José Alfredo)|||/items/6a3581ea-897b-4439-a95c-19301775e131
Abete, I. (Itziar)|||/items/2a1e4080-f97c-44d3-9098-309677a889fb
Zulet, M.A. (María Ángeles)|||/items/0a10c4f7-ed81-4b2e-bffe-fbcb7fccd239
author Mogna-Peláez, P. (Paola)|||/items/5be56ba2-bd55-4ea5-af40-e26118b537d8
author_facet Mogna-Peláez, P. (Paola)|||/items/5be56ba2-bd55-4ea5-af40-e26118b537d8
Romo‐Hualde, A. (Ana)|||/items/5c6999e7-dcc3-486f-a0e9-aa5bb6d96f4f
Riezu-Boj, J.I. (José Ignacio)|||/items/87349e89-7360-4cdd-81be-2e8a6174b5f6
Milagro-Yoldi, F.I. (Fermín Ignacio)|||/items/07cf7af6-1f5f-4720-8c14-5197a7a724eb
Muñoz-Prieto, D. (David)|||/items/c0b800f6-8ccc-4508-b8ea-6189cc7d8a99
Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1d
Elorz-Carlón, M. (Mariana)|||/items/2bb34072-5d36-4e93-baa5-317e6f1e8247
Benito-Boíllos, A. (Alberto)|||/items/36f5562b-2392-4f6a-a747-a57b8b201069
Monreal, J.I. (José Ignacio)|||/items/54707c2a-e68a-4e73-9141-0276a5bc7a2b
Tur, J.A. (Josep A.)|||/items/de6900c2-c677-4762-9a97-8e585d1c019e
Martinez, J.A. (José Alfredo)|||/items/6a3581ea-897b-4439-a95c-19301775e131
Abete, I. (Itziar)|||/items/2a1e4080-f97c-44d3-9098-309677a889fb
Zulet, M.A. (María Ángeles)|||/items/0a10c4f7-ed81-4b2e-bffe-fbcb7fccd239
author_role author
author2 Romo‐Hualde, A. (Ana)|||/items/5c6999e7-dcc3-486f-a0e9-aa5bb6d96f4f
Riezu-Boj, J.I. (José Ignacio)|||/items/87349e89-7360-4cdd-81be-2e8a6174b5f6
Milagro-Yoldi, F.I. (Fermín Ignacio)|||/items/07cf7af6-1f5f-4720-8c14-5197a7a724eb
Muñoz-Prieto, D. (David)|||/items/c0b800f6-8ccc-4508-b8ea-6189cc7d8a99
Herrero-Santos, J.I. (José Ignacio)|||/items/4df6083a-1ce6-4c19-a3fa-1b7d8bc58e1d
Elorz-Carlón, M. (Mariana)|||/items/2bb34072-5d36-4e93-baa5-317e6f1e8247
Benito-Boíllos, A. (Alberto)|||/items/36f5562b-2392-4f6a-a747-a57b8b201069
Monreal, J.I. (José Ignacio)|||/items/54707c2a-e68a-4e73-9141-0276a5bc7a2b
Tur, J.A. (Josep A.)|||/items/de6900c2-c677-4762-9a97-8e585d1c019e
Martinez, J.A. (José Alfredo)|||/items/6a3581ea-897b-4439-a95c-19301775e131
Abete, I. (Itziar)|||/items/2a1e4080-f97c-44d3-9098-309677a889fb
Zulet, M.A. (María Ángeles)|||/items/0a10c4f7-ed81-4b2e-bffe-fbcb7fccd239
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Insulin resistance
Isoliquiritigenin
Metabolomics
Nonalcoholic fatty liver disease
Visceral adipose tissue
topic Insulin resistance
Isoliquiritigenin
Metabolomics
Nonalcoholic fatty liver disease
Visceral adipose tissue
description Nonalcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease in the world. New non-invasive diagnostic tools are needed to promptly treat this disease and avoid its complications. This study aimed to find key metabolites and related variables that could be used to predict and diagnose NAFLD. Ninety-eight subjects with NAFLD and 45 controls from the Fatty Liver in Obesity (FLiO) Study (NCT03183193) were analyzed. NAFLD was diagnosed and graded by ultrasound and classified into two groups: 0 (controls) and ≥ 1 (NAFLD). Hepatic status was additionally assessed through magnetic resonance imaging (MRI), elastography, and determination of transaminases. Anthropometry, body composition (DXA), biochemical parameters, and lifestyle factors were evaluated as well. Non-targeted metabolomics of serum was performed with high-performance liquid chromatography coupled to time-of-flight mass spectrometry (HPLC-TOF-MS). Isoliquiritigenin (ISO) had the strongest association with NAFLD out of the determinant metabolites. Individuals with higher concentrations of ISO had healthier metabolic and hepatic status and were less likely to have NAFLD (OR 0.13). Receiver operating characteristic (ROC) curves demonstrated the predictive power of ISO in panel combination with other NAFLD and IR-related variables, such as visceral adipose tissue (VAT) (AUROC 0.972), adiponectin (AUROC 0.917), plasmatic glucose (AUROC 0.817), and CK18-M30 (AUROC 0.810). Individuals with lower levels of ISO have from 71 to 82% more risk of presenting NAFLD compared to individuals with higher levels. Metabolites such as ISO, in combination with visceral adipose tissue, IR, and related markers, constitute a potential non-invasive tool to predict and diagnose NAFLD.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/117295
url https://hdl.handle.net/10171/117295
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403296745127936
score 15,81155